ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Afinitor Suspension Approved For Rare Pediatric Brain Tumor

August 31, 2012

New NCI Directory

May 19, 1989

Barbara Rimer Named NCAB Chairman; First Women Appointed To Lead Board

September 16, 1994

SWOG Plans Increase in Payments to Centers for Trial Accrual.

May 25, 2007

AMC Cancer Center, Rose Cancer Program Name Douglass Tormey Director; ECG Plans Move To Denver

September 4, 1992

Drug Reimbursement: Senate Bill Worse For Oncologists

July 11, 1997